CHANGES IN LIPID METABOLISM AND RESISTIN IN PATIENTS WITH EARLY STAGES OF OBESITY-ASSOCIATED CHRONIC KIDNEY DISEASE
DOI:
https://doi.org/10.11603/1811-2471.2026.v.i2.16400Keywords:
chronic kidney disease, obesity, resistin, lipid metabolismAbstract
SUMMARY. There is a close relationship between chronic kidney disease (CKD) and obesity. Obesity affects kidney function through mechanisms of chronic inflammation, dysregulation of adipokines, activation of the renin-angiotensin-aldosterone system, and intrarenal lipid accumulation.
The aim – to assess changes in the lipid profile and dynamics of the adipokine – resistin and their relationship in patients with early stages of chronic kidney disease associated with obesity.
Material and Methods. 300 рatients with CKD were examined. Patients were divided into 4 groups: the first group consisted of 70 patients with the first stage CKD with normal body weight, the second group consisted of 72 patients with the second stage CKD with normal body weight; the third group consisted of 70 patients with the first stage CKD and obesity, and the fourth group consisted of 88 patients with the second stage CKD and obesity. The control group consisted of 30 practically healthy individuals. All participants had their BMI measured, and glomerular filtration rate (GFR) was calculated using CRD-EPI equations based on creatinine, cystatin C, and their combination (CRD-EPIcysC/cr) (ml/min/1.73 m²). The level of cystatin C, CRP, resistin, TNF-α in blood serum was determined by enzyme-linked immunosorbent assay. The level of total cholesterol, low-density lipoproteins, and high-density lipoproteins was determined by the colorimetric method.
Results. Resistin levels were higher in groups of patients with CKD and obesity. Resistin levels increased in cases of decreased GFR in patients of groups III and IV. In patients of groups III and IV, a direct correlation of medium strength was found between resistin and the WHR. In patients with CKD and obesity, as renal function decreased, an increase in triglyceride and LDL levels was observed, as well as an increase in pro-inflammatory cytokines, such as TNF-α and CRP, especially in patients with stage II CKD and obesity. High LDL and triglyceride levels correlate with both high resistin levels and higher low-grade inflammation in patients of groups III and IV.
Conclusions. In patients with CKD and obesity, increased levels of resistin have been found, which are inversely correlated with glomerular filtration rate. Also, in patients with CKD and obesity, high levels of LDL and triglycerides have been found in the blood serum, which correlate with both high levels of resistin and higher indicators of low-grade inflammation.
References
Jiang Z, Wang Y, Zhao X, Cui H, Han M, Ren X, et al. Obesity and chronic kidney disease. Am. J. Physiol. Endocrinol. Metab. 2023;324:E24–E41. DOI: 10.1152/ajpendo.00179.2022 DOI: https://doi.org/10.1152/ajpendo.00179.2022
Chang AR, Grams ME, Ballew SH, Bilo H, Correa A, Evans M, et al. Adiposity and risk of decline in glomerular filtration rate: Meta-analysis of individual participant data in a global consortium. BMJ. 2019;364:k5301. DOI: 10.1136/bmj.k5301. DOI: https://doi.org/10.1136/bmj.k5301
Boutari C, Mantzoros CS A 2022 update on the epidemiology of obesity and a call to action: As its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on. Metabolism. 2022;133:155-217. DOI: 10.1016/j.metabol. 2022.155217 DOI: https://doi.org/10.1016/j.metabol.2022.155217
Ren L, Cui H, Wang Y, Ju F, Cai Y, Gang X, et al. The role of lipotoxicity in kidney disease: From molecular mechanisms to therapeutic prospects. Biomed Pharmacother. 2023 May;161:114-465. DOI: 10.1016/j.biopha.2023. 114465. Epub 2023 Mar 3. PMID: 36870280. DOI: https://doi.org/10.1016/j.biopha.2023.114465
Suh SH, Kim SW. Dyslipidemia in Patients with Chronic Kidney Disease: An Updated Overview. Diabetes Metab J. 2023;47(5):612-29. DOI: https://doi.org/10.4093/dmj.2023.0067 Published online: July 24, 2023 DOI: https://doi.org/10.4093/dmj.2023.0067
Zhu Z, Hu J, Chen Z, Feng J, Yang X, Liang W, Ding G. Transition of acute kidney injury to chronic kidney disease: Role of metabolic reprogramming. Metabolism. 2022;131:155-194. DOI: 10.1016/j.metabol.2022.155194 DOI: https://doi.org/10.1016/j.metabol.2022.155194
Avgoustou E, Tzivaki I, Diamantopoulou G, Zachariadou T, Avramidou D, Dalopoulos V, Skourtis A. Obesity-Related Chronic Kidney Disease: From Diagnosis to Treatment. Diagnostics (Basel). 2025 Jan 14;15(2):169. DOI: 10.3390/diagnostics15020169. DOI: https://doi.org/10.3390/diagnostics15020169
An SM, Cho SH, Yoon JC. Adipose Tissue and Metabolic Health. Diabetes Metab. J. 2023;47:595–611. DOI: 10.4093/dmj.2023.0011. DOI: https://doi.org/10.4093/dmj.2023.0011
Taylor EB. The complex role of adipokines in obesity, inflammation, and autoimmunity. Clin. Sci. 2021; 135:731-752. DOI: 10.1042/CS20200895. DOI: https://doi.org/10.1042/CS20200895
Zhao S, Kusminski CM, Scherer PE. Adiponectin, Leptin and Cardiovascular Disorders. Circ. Res. 2021; 128:136-49. DOI: 10.1161/CIRCRESAHA.120.314458 DOI: https://doi.org/10.1161/CIRCRESAHA.120.314458
Acquarone E, Monacelli F, Borghi R, Nencioni A, Odetti P. Resistin: A reappraisal. Mech Ageing Dev. 2019 Mar;178:46-63. DOI: 10.1016/j.mad.2019.01.004. Epub 2019 Jan 14. PMID: 30650338.
Asgary S, Samsamshariat SZA, Sakhaei F, Salehizadeh L, Keshvari M. Relationship between Resistin, Endothelin-1, and Flow-Mediated Dilation in Patient with and without Metabolic Syndrome. Adv. Biomed. Res. 2019;8:16. DOI: 10.4103/abr.abr_126_18. DOI: https://doi.org/10.4103/abr.abr_126_18
Wang LK, Wang H, Wu XL, Shi L, Yang RM, Wang YC. Relationships among resistin, adiponectin, and leptin and microvascular complications in patients with type 2 diabetes mellitus. J. Int. Med. Res. 2020;48:0300060519870407. DOI: 10.1177/0300060519870407. DOI: https://doi.org/10.1177/0300060519870407
Zhou L, Li JY, He PP, Yu XH, Tang CK. Resistin: Potential biomarker and therapeutic target in atherosclerosis. Clin. Chim. Acta. 2021;512:84-91. DOI: 10.1016/j.cca. 2020.11.010. DOI: https://doi.org/10.1016/j.cca.2020.11.010
Guan Y, Wei Χ, Li J, Zhu Y, Luo P, Luo M. Obesity-related glomerulopathy: Recent advances in inflammatory mechanisms and related treatments. J. Leukoc. Biol. 2024;115:819-39. DOI: 10.1093/jleuko/qiae035. DOI: https://doi.org/10.1093/jleuko/qiae035
Scholz H, Boivin FJ, Schmidt-Ott KM, Bachmann S, Eckardt KU, Scholl UI, et al. Kidney physiology and susceptibility to acute kidney injury: Implications for renoprotection. Nat. Rev. Nephrol. 2021;17:335-49. DOI: 10.1038/s41581-021-00394-7. DOI: https://doi.org/10.1038/s41581-021-00394-7
Jaipal Singh, Ajit Thakur, & Dr. Ankit Singh. (2026). TNF-α associated free fatty acid flux and its contribution to insulin resistance and atherogenic dyslipidemia: a cross-sectional study. Journal of Population Therapeutics and Clinical Pharmacology. 33(1):476-486. DOI: 10.53555/ 7z8vs612
Kovesdy CP. Epidemiology of chronic kidney disease: An update 2022. Kidney Int. Suppl. 2022;12:7-11. DOI: 10.1016/j.kisu.2021.11.003. DOI: https://doi.org/10.1016/j.kisu.2021.11.003
Martínez-Montoro JI, Morales E, Cornejo-Pareja I, Tinahones FJ, Fernández-García JC. Obesity-related glomerulopathy: Current approaches and future perspectives. Obes. Rev. 2022;23:e13450. DOI: 10.1111/obr.13450. DOI: https://doi.org/10.1111/obr.13450
Zhu P, Herrington WG, Haynes R, Emberson J, Landray MJ, Sudlow CLM, et al. Conventional and Genetic Evidence on the Association between Adiposity and CKD. J. Am. Soc. Nephrol. 2021;32:127–137. DOI: 10.1681/ASN.2020050679 DOI: https://doi.org/10.1681/ASN.2020050679
Bays HE, et al. Obesity, dyslipidemia, and cardiovascular disease: a joint expert review from the obesity medicine association and the National lipid association 2024. J. Clin. Lipidol. 2024;18:e320-e350. DOI: 10.1016/j.jacl.2024.04.001 ().
Acquarone E, Monacelli F, Borghi R, Nencioni A, Odetti P. Resistin: A reappraisal. Mech. Ageing Dev. 2019;178:46-63. DOI: 10.1016/j.mad.2019.01.004. DOI: https://doi.org/10.1016/j.mad.2019.01.004
Munjas J, Sopić M, Bogavac-Stanojević N, Kravljača M, Miljković M, Simić-Ogrizović S, et al. Serum Resistin, Adenylate Cyclase-Associated Protein 1 Gene Expression, and Carotid Intima-Media Thickness in Patients with End-Stage Renal Disease and Healthy Controls. Cardiorenal. Med. 2020;10:51-60. DOI: 10.1159/000503416. DOI: https://doi.org/10.1159/000503416
Khanna D, Khanna S, Khanna P, Kahar P, Patel BM. Obesity: A Chronic Low-Grade Inflammation and Its Markers. Cureus. 2022 Feb 28;14(2):e22711. DOI: 10.7759/cureus.22711. DOI: https://doi.org/10.7759/cureus.22711
Verde L, Lucà S, Cernea S, et al. The Fat Kidney. Curr Obes Rep. 2023;12: 86-98. DOI: 10.1007/s13679-023-00500-9 DOI: https://doi.org/10.1007/s13679-023-00500-9
Taouis M, Benomar Y. Is resistin the master link between inflammation and inflammation-related chronic diseases? Mol Cell Endocrinol. 2021 Aug 1;533:111341. DOI: 10.1016/j.mce.2021.111341. Epub 2021 May 31. PMID: 34082045. DOI: https://doi.org/10.1016/j.mce.2021.111341
Lee LE, Doke T, Mukhi D, Susztak K. The key role of altered tubule cell lipid metabolism in kidney disease development. Kidney Int. 2024;106:24-34. DOI: 10.1016/j.kint.2024.02.025. DOI: https://doi.org/10.1016/j.kint.2024.02.025
Hti Lar Seng NS, Lohana P, Chandra S, Jim B. The Fatty Kidney and Beyond: A Silent Epidemic. Am. J. Med. 2023;136:965-974. DOI: 10.1016/j.amjmed.2023.06.025. DOI: https://doi.org/10.1016/j.amjmed.2023.06.025
Tisato V, Romani A, Tavanti E, Melloni E, Milani D, Bonaccorsi G, et al. Crosstalk Between Adipokines and Paraoxonase 1: A New Potential Axis Linking Oxidative Stress and Inflammation. Antioxidants. 2019;8:287. DOI: 10.3390/antiox8080287. DOI: https://doi.org/10.3390/antiox8080287
Romejko K, Rymarz A, Szamotulska K, Bartoszewicz Z, Rozmyslowicz T, Niemczyk S. Resistin Contribution to Cardiovascular Risk in Chronic Kidney Disease Male Patients. Cells. 2023 Mar 24;12(7):999. DOI: 10.3390/cells12070999. DOI: https://doi.org/10.3390/cells12070999
Kjeldsen EW, Thomassen JQ, Frikke-Schmidt R. HDL cholesterol concentrations and risk of atherosclerotic cardiovascular disease - Insights from randomized clinical trials and human genetics. Biochim Biophys Acta Mol Cell Biol Lipids. 2022 Jan;1867(1):159063. DOI: 10.1016/j.bbalip.2021.159063. Epub 2021 Oct 9. DOI: https://doi.org/10.1016/j.bbalip.2021.159063
Yanai H, Yoshida H. Beneficial Effects of Adiponectin on Glucose and Lipid Metabolism and Atherosclerotic Progression: Mechanisms and Perspectives. Int J Mol Sci. 2019 Mar 8;20(5):1190. DOI: 10.3390/ijms20051190. DOI: https://doi.org/10.3390/ijms20051190
Chait A, den Hartigh LJ. Adipose Tissue Distribution, Inflammation and Its Metabolic Consequences, Including Diabetes and Cardiovascular Disease. Front Cardiovasc Med. 2020 Feb 25;7:22. DOI: 10.3389/fcvm. 2020.00022. DOI: https://doi.org/10.3389/fcvm.2020.00022
Bays HE, Kirkpatrick CF, Maki KC, Toth PP, Morgan RT, Tondt J, et al. Obesity, dyslipidemia, and cardiovascular disease: A joint expert review from the Obesity Medicine Association and the National Lipid Association 2024. J Clin Lipidol. 2024 May-Jun;18(3):e320-e350. DOI: 10.1016/j.jacl.2024.04.001. Epub 2024 Apr 24. DOI: https://doi.org/10.1016/j.jacl.2024.04.001
